Hochhaus, A. et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N. Engl. J. Med. 376, 917–927 (2017).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jiang, V. C. et al. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma. J. Clin. Invest. 133, e165694 (2023).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shaffer, A. L. 3rd et al. Overcoming acquired epigenetic resistance to BTK inhibitors. Blood Cancer Discov 2, 630–647 (2021).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kadri, S. et al. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. 1, 715–727 (2017).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19–34 (2017).

Article  PubMed  CAS  Google Scholar 

Sun, Y. et al. Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas. Leukemia 33, 2105–2110 (2019).

Article  PubMed  Google Scholar 

Buhimschi, A. D. et al. Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-Mediated Degradation. Biochemistry 57, 3564–3575 (2018).

Article  PubMed  CAS  Google Scholar 

Shorer Arbel, Y. et al. Proteolysis targeting chimeras for BTK efficiently inhibit B-cell receptor signaling and can overcome ibrutinib resistance in CLL cells. Front. Oncol. 11, 646971 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Cao, S. et al. Proteolysis-targeting chimera (PROTAC) modification of dovitinib enhances the antiproliferative effect against FLT3-ITD-positive acute myeloid leukemia cells. J. Med. Chem. 64, 16497–16511 (2021).

Article  PubMed  CAS  Google Scholar 

Zhao, Q. et al. Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. J. Med. Chem. 62, 9281–9298 (2019).

Article  PubMed  CAS  Google Scholar 

Sun, N. et al. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. Eur. J. Med. Chem. 193, 112190 (2020).

Article  PubMed  CAS  Google Scholar 

Liu, J. et al. TF-PROTACs enable targeted degradation of transcription factors. J. Am. Chem. Soc. 143, 8902–8910 (2021).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bond, M. J. et al. Targeted degradation of oncogenic KRAS(G12C) by VHL-recruiting PROTACs. ACS Cent. Sci. 6, 1367–1375 (2020).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Samarasinghe, K. T. G. et al. OligoTRAFTACs: a generalizable method for transcription factor degradation. RSC Chem. Biol. 3, 1144–1153 (2022).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu, S. et al. BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting ‘Undruggable’ Myc-pathway genes. Cancer Cell Int. 21, 230 (2021).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Xu, Y. et al. The aptamer-based RNA-PROTAC. Bioorg. Med. Chem. 86, 117299 (2023).

Article  PubMed  CAS  Google Scholar 

Lai, A. C. & Crews, C. M. Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16, 101–114 (2017).

Article  PubMed  CAS  Google Scholar 

Kenten John, H. & Roberts Steven, F. Controlling Protein Levels in Eucaryotic Organisms. US7273920 (1999).

Liu, Z. et al. An overview of PROTACs: a promising drug discovery paradigm. Mol. biomed. 3, 46 (2022).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schreiber, S. L. The rise of molecular glues. Cell 184, 3–9 (2021).

Article  PubMed  CAS  Google Scholar 

Wells, J. A. & Kumru, K. Extracellular targeted protein degradation: an emerging modality for drug discovery. Nat. Rev. Drug Discov. 23, 126–140 (2024).

Article  PubMed  Google Scholar 

Paudel, R. R. et al. Targeted protein degradation via lysosomes. Biochemistry 62, 564–579 (2023).

Article  PubMed  CAS  Google Scholar 

Eldridge, A. G. & O’Brien, T. Therapeutic strategies within the ubiquitin proteasome system. Cell Death Differ 17, 4–13 (2010).

Article  PubMed  CAS  Google Scholar 

Kimura, Y. & Tanaka, K. Regulatory mechanisms involved in the control of ubiquitin homeostasis. J. Biochem. 147, 793–798 (2010).

Article  PubMed  CAS  Google Scholar 

Cecchini, C., Pannilunghi, S., Tardy, S. & Scapozza, L. From conception to development: investigating PROTACs features for improved cell permeability and successful protein degradation. Front Chem 9, 672267 (2021).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98, 8554–8559 (2001).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Edmondson, S. D., Yang, B. & Fallan, C. Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges. Bioorg. Med. Chem. Lett. 29, 1555–1564 (2019).

Article  PubMed  CAS  Google Scholar 

Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611–617 (2015).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schneekloth, A. R., Pucheault, M., Tae, H. S. & Crews, C. M. Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. Bioorg. Med. Chem. Lett. 18, 5904–5908 (2008).

Article  PubMed  CAS  Google Scholar 

Li, J. et al. A platform for the rapid synthesis of molecular glues (Rapid-Glue) under miniaturized conditions for direct biological screening. Eur. J. Med. Chem. 258, 115567 (2023).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dewey, J. A. et al. Molecular glue discovery: current and future approaches. J. Med. Chem. 66, 9278–9296 (2023).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Domostegui, A., Nieto-Barrado, L., Perez-Lopez, C. & Mayor-Ruiz, C. Chasin